An ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and GMP Certified Company

CAS NO: 2374-03-0 Manufacturers

CAS NO: 2374-03-0 MANUFACTURERS

4-Amino-3-Hydroxy Benzoic Acid

Vasista are one of the leading CAS NO: 2374-03-0 Manufacturers in india that provide high-quality drugs for various requirements. Established in 2010, we employ good manufacturing practices and thus are An ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and GMP Certified Company.

CAS NO: 2374-03-0 Manufacturers - 4-Amino-3-Hydroxy Benzoic Acid is a chemical compound used as an intermediate during the synthesis of tafamidis. The chemical compound used to produce tafamidis

With advancements in the medical field, access to such life-saving drugs is easier, which in turn increases its demand. This leads to a whole new challenge of maintaining the integrity of drugs to ensure they are safe and effective. Vasista Life Sciences is a leading CAS NO: 2374-03-0 Manufacturers that specialises in the production of bulk drug intermediates, metal reagents, grignard agents, and fine chemicals among others. Founded 15 years back, we have grown in leaps and bounds over the years offering our clients a wide portfolio of high-quality drugs for various medical requirements. With a rich track record of innovation, intermediate exporters, and top-notch customer service, we adhere to numerous quality regulations including GxP in all aspects of our work.

Product Informations:

  • CAS Number: 2374-03-0
  • Molecular Formula:C7H7NO3
  • Molecular Weight: 153.14
  • Synonyms: benzoic acid, 4-amino-3-hydroxy-;

It is an intermediate for Tafamidis. Tafamidis is used to delay nerve damage in adults who have transthyretin amyloidosis with polyneuropathy, or heart disease in adults who have transthyretin amyloidosis with cardiomyopathy.

We also manufacture the following intermediates of Tafamidis:

Name Of The Materials Cas No.
3,5-Dichlorobenzoyl Chloride 2905-62-6

As a leading CAS NO: 2374-03-0 Manufacturers, we strive to meet every aspect of the work while trying to improve patient outcomes and enhance the effectiveness of our drugs.

Previous: Cas no: 202189-76-2

Next: Cas no: 29943-42-8

Brochure